LivaNova Reports Second Quarter 2021 Results and Appoints Alex Shvartsburg as Chief

Financial Officer, 28.07.2021

LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2021.

For the second quarter of 2021, worldwide sales from continuing operations were $264.5 million, an increase of 45.2 percent on a reported basis and 41.0 percent on a constant-currency1 basis, as compared to the same quarter of the previous year. Worldwide sales from continuing operations for the second quarter of 2021, excluding sales related to the Heart Valves business that was divested effective June 1 as part of the initial closing, were $249.8 million, an increase of 51.6 percent on a reported basis and 47.6 percent on a constant-currency1 basis, as compared to the same quarter of the previous year. On the basis of U.S. Generally Accepted Accounting Principles (GAAP), second quarter 2021 diluted loss per share from continuing operations was $1.13. Second quarter 2021 adjusted diluted earnings per share from continuing operations was $0.52.

“As we navigate shifting market dynamics resulting from the pandemic, we continue to gain momentum in Epilepsy sales growth across all regions,” said Damien McDonald, Chief Executive Officer of LivaNova. “Procedure volumes in Neuromodulation continue to recover, especially replacement implant volumes. Across our businesses, certain countries in our Europe and Rest of World regions remain challenged by COVID-19. Looking ahead, we are focused on delivering critical medical devices and therapies to significant patient populations, while managing our core businesses to drive profitability and cash generation. We also remain committed to investing in our pipeline and taking the appropriate actions to position our business for long-term growth.”

https://investor.livanova.com/index.php/news-releases/news-release-details/livanova-reports-second-quarter-2021-results-and-appoints-alex

Pressekontakt

Resuscitec GmbH
Engesserstraße 4
D-79108 Freiburg
press@resuscitec.de


Disclaimer

Sie erhalten das Presseclipping der Resuscitec GmbH aufgrund Ihrer Beziehung zu unserem Unternehmen. Wir verarbeiten Ihre Daten auf Grundlage unseres berechtigten Interesses zum Zweck der persönlichen Ansprache und zum Versand unseres Presseclippings. Verantwortlich für die Datenverarbeitung ist die Resuscitec GmbH. Weitere Informationen zum Datenschutz finden Sie in unseren Datenschutzhinweisen. Sie können der Verarbeitung Ihrer personenbezogenen Daten für den Versand des Presseclippings jederzeit formlos widersprechen.


Nutzungshinweis

Aus urheberrechtlichen Gründen dürfen die Artikel weder in digitaler noch ausgedruckter Form an Dritte weitergegeben werden. Sie sind nur zum persönlichen Gebrauch bestimmt, der Aufbau einer Datenbank mit digitalisierten Artikeln ist nicht erlaubt.